المؤلفون: M. A. Stenina, T. V. Gromova, V. V. Grechenko, L. V. Gankovskaya

المصدر: Медицинская иммунология, Vol 26, Iss 6, Pp 1315-1321 (2024)

مصطلحات موضوعية: γδt cells, flow cytometry, older patients, gastric ulcer, intestinal dysbiosis, gastrointestinal tract mucosa, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: https://www.mimmun.ru/mimmun/article/view/2889; https://doaj.org/toc/1563-0625; https://doaj.org/toc/2313-741X

URL الوصول: https://doaj.org/article/9b8a76c97d264fb8bfc8c335a28f0fef

المؤلفون: S. I. Kudryashov, M. A. Stenina, L. M. Karzakova, T. S. Lutkova

المصدر: Медицинская иммунология, Vol 26, Iss 1, Pp 181-190 (2024)

مصطلحات موضوعية: immunosuppression, glomerulonephritis, recombinant interleukin-2, nephrotic syndrome, treg cells, treatment of glomerulonephritis, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: https://www.mimmun.ru/mimmun/article/view/2670; https://doaj.org/toc/1563-0625; https://doaj.org/toc/2313-741X

URL الوصول: https://doaj.org/article/b9bc3e35690f4a99865041bcc4fb45b9

المؤلفون: S. A. Tjulandin, M. B. Stenina, M. A. Frolova, С. А. Тюляндин, М. Б. Стенина, М. А. Фролова

المصدر: Malignant tumours; Принято в печать ; Злокачественные опухоли; Принято в печать ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: генетический тест, chemotherapy, test hormonotherapy, genetic tests, химиотерапия, тестовая гормонотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1309/932; Ferreira A.R., Di Meglio A., Pistilli B. et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol 2019;30(11):1784-1795. https://doi.org/10.1093/annonc/mdz298; Sparano J.A., Gray R.J., Makower D.F. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379(2):111-121. https://doi.org/10.1056/NEJMoa1804710; Kalinsky K., Barlow W.E., Gralow J.R. et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 2021;385(25):2336-2347. https://doi.org/10.1056/NEJMoa2108873; Kalinsky K., Barlow W.E., Meric-Bernstam F. et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Cancer Research 2021;81(4_Supplement):GS3-00-GS3-00. https://doi.org/10.1158/1538-7445.SABCS20-GS3-00; Sparano J.A., Gray R.J., Ravdin P.M. et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-2405. https://doi.org/10.1056/NEJMoa1904819; Fabrice A., Ismaila N., Kimberly H.A. et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update. J Clin Oncol 2022;40(16):1816-1837. https://doi.org/10.1200/JCO.22.00069; Curigliano G., Burstein H.J., Gnant M. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 2023;34(11):970-986. https://doi.org/10.1016/j.annonc.2023.08.017; Orucevic A., Bell J.L., King M. et al. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast 2019;46:116-125. https://doi.org/10.1016/j.breast.2019.05.006; Smith I., Robertson J., Kilburn L. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal patients with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020;21(11):1443-1454. https://doi.org/10.1016/S1470-2045(20)30458-7; Burstein H.J., Curigliano G., Thürlimann B. et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021;32(10):1216-1235. https://doi.org/10.1016/j.annonc.2021.06.023; Francis P.A., Pagani O., Fleming G.F. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379(2):122-137. https://doi.org/10.1056/NEJMoa1803164; Pagani O., Walley B.A., Fleming G.F. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 2023;41(7):1376-1382. https://doi.org/10.1200/JCO.22.01064; Regan M.M., Francis P.A., Pagani O. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016;34(19):2221-2231. https://doi.org/10.1200/JCO.2015.64.3171; https://www.malignanttumors.org/jour/article/view/1309

الاتاحة: https://www.malignanttumors.org/jour/article/view/1309
https://doi.org/10.18027/2224-5057-2024-003

المؤلفون: M. A. Frolova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 20, Pp 156-159 (2021)

مصطلحات موضوعية: her2-positive metastatic breast cancer, double anti-her2 blockade, trastuzumab, pertuzumab, eribulin, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6594; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/1966b5f19b234fa8a3a8fe228bc7064f

المؤلفون: M. A. Frolova, M. B. Stenina, М. А. Фролова, М. Б. Стенина

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 41-47 ; Медицинский Совет; № 11 (2023); 41-47 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: алпелисиб, fulvestrant, selective estrogen receptor degraders, ESR1 mutations, PIK3CA mutations, alpelisib, фулвестрант, селективные дегрейдеры рецепторов эстрогена, ESR1 мутации, PIK3CA мутации

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7667/6801; Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.; Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. https://doi.org/10.1146/annurevmed-070909-182917.; Gottardis M.M., Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183–5187. Available at: https://pubmed.ncbi.nlm.nih.gov/3409244/.; Gottardis M.M., Wagner R.J., Borden E.C., Jordan V.C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in Vivo and in Vitro. Cancer Res. 1989;49(17):4765–4769. Available at: https://pubmed.ncbi.nlm.nih.gov/2758410/.; Gottardis M.M., Jiang S.-Y., Jeng M.-H., Jordan V.С. Inhibition of tamoxifenstimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090–4093. Available at: https://pubmed.ncbi.nlm.nih.gov/2743303/.; Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.С. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990;50(11): 3189–3192. Available at: https://pubmed.ncbi.nlm.nih.gov/2334915/.; Bowler J., Lilley T.J., Pittam J.D., Wakeling A.E. Novel steroidal pure antiestrogens. Steroids. 1989;54(1):71–99. https://doi.org/10.1016/0039-128x(89)90076-7.; Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–3873. Available at: https://pubmed.ncbi.nlm.nih.gov/1855205/.; Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106(Pt 4):1377–1388. https://doi.org/10.1242/jcs.106.4.1377.; Osborne C.K., Wakeling A., Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(1 Suppl.):S2–S6. https://doi.org/10.1038/sj.bjc.6601629.; Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000;89(4):817–825. https://doi.org/10.1002/1097-0142(20000815)89:43.0.co;2-6.; Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B. et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8(1):21–30. https://doi.org/10.1210/mend.8.1.8152428.; Nicholson R.I., Gee J.M., Manning D.L., Wakeling A.E., Montano M.M., Katzenellenbogen B.S. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 1995;761:148–163. https://doi.org/10.1111/j.1749-6632.1995.tb31376.x.; Harrison M., Laight A., Clarke D., Giles P., Yates Y. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. EJC. 2003;1(5):S171. https://doi.org/10.1016/s1359-6349(03)90596-9.; Robertson J.F., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol. 2003;52(4):346–348. https://doi.org/10.1007/s00280-003-0643-7.; McCormack P., Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor–positive advanced breast cancer. Clin Breast Cancer. 2008;8(4):347–351. https://doi.org/10.3816/CBC.2008.n.040.; Ohno S., Rai Y., Iwata H., Yamamoto N., Yoshida M., Iwase H. et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–2347. https://doi.org/10.1093/annonc/mdq249.; Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396–3403. https://doi.org/10.1200/JCO.2002.10.057.; Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058.; Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605–1613. https://doi.org/10.1200/JCO.2004.02.112.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600. https://doi.org/10.1200/JCO.2010.28.8415.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337. https://doi.org/10.1093/jnci/djt337.; Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E. et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–4535. https://doi.org/10.1200/JCO.2008.21.1136.; Robertson J.F., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3.; Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. https://doi.org/10.1200/JCO.2017.75.6155.; Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., PaluchShimon S. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709.; Sledge G.W. Jr, Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. https://doi.org/10.1200/JCO.2017.73.7585.; Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. https://doi.org/10.1016/S1470-2045(15)00613-0.; Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909.; Llombart-Cussac A., Pérez-García J.M., Bellet M., Dalenc F., Gil-Gil M., RuízBorrego M. et al. PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–1799. https://doi.org/10.1001/jamaoncol.2021.4301.; Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L. et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998. https://doi.org/10.1016/S1470-2045(13)70322-X.; Fribbens C., O’Leary B., Kilburn L., Hrebien S., Garcia-Murillas I., Beaney M. et al. Plasma ESR1 mutations and the treatment of estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–2968. https://doi.org/10.1200/JCO.2016.67.3061.; Giuliano M., Schettini F., Rognoni C., Milani M., Jerusalem G., Bachelot T. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. https://doi.org/10.1016/S1470-2045(19)30420-6.; Wilson F.R., Varu A., Mitra D., Cameron C., Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167–177. https://doi.org/10.1007/s10549-017-4404-4.; André F., Ciruelos E., Rubovszky G., Campone M., Rugo H.S., Iwata H. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904.; Rugo H.S., Neven P., Saffie I., Park Y.H., De Laurentiis M., Lerebours F. et al. Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2– advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses. Cancer Res. 2022;82(4):PD13–05. https://doi.org/10.1158/1538-7445.SABCS21-PD13-05.; https://www.med-sovet.pro/jour/article/view/7667

الاتاحة: https://www.med-sovet.pro/jour/article/view/7667
https://doi.org/10.21518/ms2023-189

المؤلفون: M. A. Frolova, E. V. Glazkova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 9, Pp 148-153 (2021)

مصطلحات موضوعية: metastatic er positive her2 negative breast cancer, oral vinorelbine, metronomic chemotherapy regimen, combined endocrine therapy, inhibitors of cyclin-dependent kinases 4/6, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6266; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/f56d2d36f50d4500b9269725568761c6

المؤلفون: E. V. Artamonova, E. I. Kovalenko, L. V. Bolotina, M. B. Stenina, R. V. Orlova, M. A. Mukhina

المصدر: Опухоли женской репродуктивной системы, Vol 16, Iss 3, Pp 37-45 (2021)

مصطلحات موضوعية: metastatic breast cancer, cdk4/6 inhibitors, palbociclib, russian clinical practice, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://ojrs.abvpress.ru/ojrs/article/view/765; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627

URL الوصول: https://doaj.org/article/640a20fdf7f74bcf91ba6e8ec246f550

المؤلفون: M. A. Frolova, E. V. Glazkova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 9, Pp 57-61 (2020)

مصطلحات موضوعية: brca-associated breast cancer, parp inhibitors, metastatic triple negative breast cancer, olaparib, talazoparib, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/5701; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/110cf705e39d4199ac8ebdb1b54be815

المؤلفون: T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin

المصدر: Антибиотики и Химиотерапия, Vol 63, Iss 1-2, Pp 24-31 (2020)

مصطلحات موضوعية: ercc1, serous ovarian cancer, platinum-based chemotherapy, flow cytometry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.antibiotics-chemotherapy.ru/jour/article/view/65; https://doaj.org/toc/0235-2990

URL الوصول: https://doaj.org/article/1cf2797fa36d45f4b262fec22b867e8f

المؤلفون: M. A. Frolova, M. В. Stenina, М. А. Фролова, М. Б. Стенина

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2022); 30-35 ; Медицинский Совет; № 22 (2022); 30-35 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: фулвестрант, CDK 4/6 inhibitors, hormone therapy, palbociclib, aromatase inhibitors, fulvestrant, ингибиторы циклинзависимых киназ 4/6, гормонотерапия, палбоциклиб, ингибиторы ароматазы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7242/6485; Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., Andre F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649. https://doi.org/10.1016/j.annonc.2020.09.010.; Тюляндин С.А., Жукова Л.Г., Королева И.А., Пароконная А.А., Семиглазова Т.Ю., Стенина М.Б., Фролова М.А. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2021;(3s2-1):119-157. https://doi.org/10.18027/2224-5057-2021-11-3s2-09.; Gennari A., Andre F., Barrios C.H, Cortes J., de Azambuja E., DeMichele A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-1495. https://doi.org/10.1016/j.annonc.2021.09.019.; Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936. https://doi.org/10.1056/NEJMoa1607303.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Paluch-Shimon S. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748. https://doi.org/10.1056/NEJMoa1609709.; Johnston S., Martin M., Di Leo A., Im S.A., Awada A., Forrester T. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:1-5. https://doi.org/10.1038/s41523-018-0097-z.; Giuliano M., Schettini F., Rognoni C., Milani M., Jerusalem G., Bachelot T. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360-1369. https://doi.org/10.1016/S1470-2045(19)30420-6.; Wilson F.R., Varu A., Mitra D., Cameron C., Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167-177. https://doi.org/10.1007/s10549-017-4404-4.; Rugo H.S., Finn R.S., Dieras V., Ett J., Lipatov O., Joy A.A. et al. Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups. Cancer Res. 2018;78(4 Suppl.):P5-21-03. https://doi.org/10.1158/1538-7445.SABCS17-P5-21-03.; Di Leo A., Dickler M., Sledge G.W., Toi M., Forrester T., Nanda S. et al. Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. Cancer Res. 2018;78(Suppl.4):P5-21-02. https://doi.org/10.1158/1538-7445.SABCS17-P5-21-02.; Sano M.V., Martorana F., Lavenia G., Rossello R., Prestifilippo A., Sava S. et al. Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. Expert Rev Anticancer Ther. 2022;22(4):343-351. https://doi.org/10.1080/14737140.2022.2052277.; Verma S., O'Shaughnessy J., Burris H.A., Campone M., Alba E., Chandiwana D. et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018;170(3):535-545. https://doi.org/10.1007/s10549-018-4769-z.; Rugo H.S., Dieras V., Gelmon K.A., Finn R.S., Slamon D.J., Martin M. et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888-894. https://doi.org/10.1093/annonc/mdy012.; Goetz M.P., Martin M., Tokunaga E., Park I.H., Huober J., Toi M. et al. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist. 2020;25(9):e1346-e1354. https://doi.org/10.1634/theoncologist.2020-0084.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G., Hart L. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. https://doi.org/10.1056/NEJMoa2114663.; Goetz M., Toi M., Huober J., Sohn J., Tredan O., Park I.H. et al. MONARCH 3: Interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer. Ann Oncol. 2022;33(7 Suppl.):S808-S869. https://doi.org/10.1016/annonc/annonc1089.; Finn R.S., Rugo H.S, Dieras V.C., Harbeck N., Im S.A., Gelmon K.A. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2. J Clin Oncol. 2022;40(17). https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003.; Corrigan-Curay J., Sacks L., Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867- https://doi.org/868.10.1001/jama.2018.10136.; Brufsky A., Liu X., Li B., McRoy L., Layman R.M. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis. Front Oncol. 2022;4;12:865292. https://doi.org/10.3389/fonc.2022.865292.; Rugo H.S., Brufsky A., Liu X., Li B., McRoy L., Chen C. et al. Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. Ann Oncol. 2022;33(3 Suppl.):S194-S223.; Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. https://doi.org/10.1016/S1470-2045(15)00613-0.; Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-2472. https://doi.org/10.1200/JCO.2018.78.9909.; Sledge G.W.Jr., Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. https://doi.org/10.1200/JCO.2017.73.7585.; Llombart-Cussac A., Perez-Garda J.M., Bellet M., Dalenc F., Gil-Gil M., Rwz-Borrego M. et al. PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791-1799. https://doi.org/10.1001/jamaoncol.2021.4301.; Andre F., Ciruelos E., Rubovszky G., Campone M., Rugo H.S., Iwata H. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940. https://doi.org/10.1056/NEJMoa1813904.; https://www.med-sovet.pro/jour/article/view/7242

الاتاحة: https://www.med-sovet.pro/jour/article/view/7242
https://doi.org/10.21518/2079-701X-2022-16-22-4

المؤلفون: L. V. Matveeva, L. M. Mosina, M. A. Stenina

المصدر: RUDN Journal of Medicine, Vol 23, Iss 3, Pp 250-256 (2019)

مصطلحات موضوعية: vascular endothelial growth factor, granulocyte-macrophage colony stimulating factor, erythropoietin, chronic gastritis, diagnostic value, Medicine

وصف الملف: electronic resource

Relation: http://journals.rudn.ru/medicine/article/viewFile/22513/17600; https://doaj.org/toc/2313-0245; https://doaj.org/toc/2313-0261

URL الوصول: https://doaj.org/article/5d1e7d5e0c024fc8a78717ee29deee5b

المؤلفون: E. V. Glazkova, M. A. Frolova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 19, Pp 69-72 (2019)

مصطلحات موضوعية: metastatic triple negative breast cancer, ixabepilone, capecitabine, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/5179; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/4c8d00ef23ee464c9c50713b8716a54b

المؤلفون: S. F. Menshikova, M. A. Frolova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 10, Pp 129-134 (2019)

مصطلحات موضوعية: breast cancer, trastuzumab, capecitabine, lapatinib, brain metastases, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/3063; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/6e700bf891024efe8ec29841f50d1b46

المؤلفون: A A Avalyan, E V Oshchepkova, M A Saidova, V N Shitov, E V Glazkova, M B Stenina, I E Chazova

المصدر: Системные гипертензии, Vol 15, Iss 4, Pp 59-64 (2018)

مصطلحات موضوعية: cardiooncology, arterial hypertension, cardiotoxicity, chemotherapy, breast cancer, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://syst-hypertension.ru/2075-082X/article/viewFile/29629/pdf; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/464c82ba1b4a42c48ada51931c7bef0e

المؤلفون: I Ye Chazova, S A Tyulyandin, M V Vitsenia, E P Panchenko, Yu A Fedotkina, M G Poltavskaya, M Yu Gilyarov, T V Martynyuk, A G Ovchinnikov, M B Stenina, O P Trophimova, F T Ageev

المصدر: Системные гипертензии, Vol 15, Iss 1, Pp 6-20 (2018)

مصطلحات موضوعية: chemotherapy, radiotherapy, thromboembolism, cardiotoxicity, diagnosis, prevention, treatment, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://syst-hypertension.ru/2075-082X/article/viewFile/29589/pdf; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/4e54fc60141c4cd4be0441b1806c447a

المؤلفون: I Ye Chazova, S A Tyulyandin, M V Vitsenia, A G Ovchinnikov, M G Poltavskaya, M Yu Gilyarov, T V Martynyuk, E P Panchenko, Yu A Fedotkina, M B Stenina, O P Trophimova, F T Ageev

المصدر: Системные гипертензии, Vol 14, Iss 3, Pp 6-20 (2017)

مصطلحات موضوعية: cardiotoxicity, chemotherapy, anthracyclines, trastuzumab, left ventricular dysfunction, heart failure, diagnosis, prevention, treatment, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://syst-hypertension.ru/2075-082X/article/viewFile/29580/pdf; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/0ece9a1172ea4985b491affe3e8ebe55

المؤلفون: A A Avalyan, M Yu Kirillova, V N Shitov, Ye V Oshchepkova, M A Saidova, M B Stenina, I Ye Chazova

المصدر: Системные гипертензии, Vol 14, Iss 3, Pp 21-27 (2017)

مصطلحات موضوعية: cardio-oncology, arterial hypertension, cardiotoxicity, global longitudinal strain of the left ventricle, chemotherapy, breast cancer, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://syst-hypertension.ru/2075-082X/article/viewFile/29581/pdf; https://doaj.org/toc/2075-082X; https://doaj.org/toc/2542-2189

URL الوصول: https://doaj.org/article/00bd6b114a904b0ebb1c56da122870bb

المؤلفون: M. A. Frolova, Е. V. Glazkova, A. V. Petrovsky, О. V. Krokhina, M. В. Stenina, S. A. Tyulyandin, М. А. Фролова, Е. В. Глазкова, А. В. Петровский, О. В. Крохина, М. Б. Стенина, С. А. Тюляндин

المصدر: Malignant tumours; Том 10, № 2 (2020); 45-52 ; Злокачественные опухоли; Том 10, № 2 (2020); 45-52 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: HER2-позитивный рак молочной железы, HER2‑positive breast cancer

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/741/510; Rivenbark, A.G. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine / A.G.Riverbank, S.M. O’Connor, W.B.Coleman //Am J Path. — 2013. — 183(4). — P. 1113 1124.; Cortazar, P. Pathological complete response and long term clinical benefit in breast cancer: the CTNeoBC pooled analysis / P. Cortazar, L. Zhang, M. Untch et al. // Lancet. — 2014. — Jul 12. — 384 (9938). — P. 164 72.; Baselga, J. Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial / J. Baselga, I. Bradbury, H. Eidtmann et al. // Lancet. — 2012. — 379. — P. 633 40.; Gianni, L. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, infl ammatory, or early HER2 positive breast cancer (NeoSphere): a randomised multicentre, open label, phase 2 trial / L. Gianni, T. Pienkowski, Y.H. Im et al. // Lancet Oncol. — 2012. — 13. — P. 25 32.; Schneeweiss, A. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline containing and anthracycline free chemotherapy regimens in patients with HER2 positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) / A. Schneeweiss, S. Chia, T. Hickish et al. // Ann Oncol. — 2013. — 24. — P. 2278 2284.; Pegram, M.D. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer / M.D. Pegram, G.E. Konecny, C. O’Callaghan et al. // J Natl Cancer Inst. — 2004. — 96. — P. 739 49.; von Minckwitz, G. Neoadjuvant carboplatin in patients with triple negative and HER2 positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial / G. von Minckwitz, A. Schneeweiss, S. Loibl et al. // Lancet Oncol. — 2014. — 15(7). — 747e56.; Symmans, W.F. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy / W.F. Symmans, F. Peintinger, C. Hatzis et al. // J Clin Oncol. — 2007. — Oct 1. — 25(28). — P. 4414 22.; Untch, M. Neoadjuvant Treatment With Trastuzumab in HER2 Positive Breast Cancer: Results From the GeparQuattro Study / M. Untch, M. Rezai, S. Loibl et al. // JCO. — 2010. — Vol. 28, N 12. — April 20.; Denkert, C. Tumor Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2 Positive and Triple Negative Primary Breast Cancers / C. Denkert, G. von Minckwitz, J.C. Brase et al. // J Clin Oncol. — 2015. — Mar 20. — 33(9). — P. 983 91.; Hamy, A.S. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease free survival in HER2 positive breast cancer /A.S. Hamy, J.Y. Pierga, A. Sabaila // Ann Oncol. — 2017. — 28. — P. 2233 2240.; Sheri, A. Residual proliferative cancer burden to predict longterm outcome following neoadjuvant chemotherapy /A. Sheri, I.E. Smith, S.R. Johnston // Ann Oncol. — 2015. — 26. — P. 75 80.; von Minckwitz, G. Trastuzumab Emtansine for Residual Invasive HER2 Positive Breast Cancer / G. von Minckwitz, C.S. Huang, M.S. Mano et al. // N Engl J Med. — 2019. — Feb 14. — 380(7). — P. 617 628.; https://www.malignanttumors.org/jour/article/view/741

الاتاحة: https://www.malignanttumors.org/jour/article/view/741
https://doi.org/10.18027/2224-5057-2020-10-2-4

المؤلفون: S. F. Menshikova, M. A. Frolova, E. V. Glazkova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 19, Pp 28-30 (2018)

مصطلحات موضوعية: metastatic hormone-dependent breast cancer, hormone therapy, cyclin-dependent kinase inhibitors, ribociclib, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/2743; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/13b79c9efaba4013bdb873623360288f

المؤلفون: M. A. Frolova, E. B. Glazkova, M. B. Stenina

المصدر: Медицинский совет, Vol 0, Iss 10, Pp 158-160 (2018)

مصطلحات موضوعية: her2-negative metastatic hormone-dependent breast cancer, hormone therapy, palbociclib, letrozole, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/2550; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/5ff8b028fe6f43a291a5693e53af21f5